Covidien (NYSE:COV) touted study results showing that the Barrett’s esophagus treatment it acquired along with Barrx 2 years ago reduces pre-cancerous tissue.
The Mansfield, Mass.-based medical device company said the 136-patient Surf trial compared treating Barrett’s, in which pre-cancerous tissue lines the windpipe, using the Barrx radiofrequency ablation device with just observation.
The most common adverse event was narrowing of the esophagus, which occurred in 10% of patients, according to a press release.
Covidien, which acquired Barrx in 2011 for $325 million, launched its Halo60 ablation catheter for Barrett’s esophagus In March 2012.